JP4475406B2 - 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 - Google Patents
異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 Download PDFInfo
- Publication number
- JP4475406B2 JP4475406B2 JP2004524883A JP2004524883A JP4475406B2 JP 4475406 B2 JP4475406 B2 JP 4475406B2 JP 2004524883 A JP2004524883 A JP 2004524883A JP 2004524883 A JP2004524883 A JP 2004524883A JP 4475406 B2 JP4475406 B2 JP 4475406B2
- Authority
- JP
- Japan
- Prior art keywords
- benzofuran
- dihydro
- carboxylic acid
- chloro
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FHIQLPQRFYGADP-UHFFFAOYSA-N CC(Cc1c2)(C(O)=O)Oc1ccc2OCCCOc(c(Cl)c1)ccc1OCC(F)(F)F Chemical compound CC(Cc1c2)(C(O)=O)Oc1ccc2OCCCOc(c(Cl)c1)ccc1OCC(F)(F)F FHIQLPQRFYGADP-UHFFFAOYSA-N 0.000 description 1
- PMFWUTPSHKGQPZ-UHFFFAOYSA-N CC(Cc1c2)(C(O)=O)Oc1ccc2OCCC[O-]c(ccc(OC(F)(F)F)c1)c1Cl Chemical compound CC(Cc1c2)(C(O)=O)Oc1ccc2OCCC[O-]c(ccc(OC(F)(F)F)c1)c1Cl PMFWUTPSHKGQPZ-UHFFFAOYSA-N 0.000 description 1
- SFYMQKHUHLWZSR-UHFFFAOYSA-N CCCc(cc(CC(C)(C)C)cc1)c1OCCCOc(cc1C2)ccc1OC2(C)C(O)=O Chemical compound CCCc(cc(CC(C)(C)C)cc1)c1OCCCOc(cc1C2)ccc1OC2(C)C(O)=O SFYMQKHUHLWZSR-UHFFFAOYSA-N 0.000 description 1
- UGDBCWMWCMYMBN-UHFFFAOYSA-N CCCc(cc(CC(C)(C)C)cc1)c1OCCCOc(cc1C2)ccc1OC2(CC)C(O)=O Chemical compound CCCc(cc(CC(C)(C)C)cc1)c1OCCCOc(cc1C2)ccc1OC2(CC)C(O)=O UGDBCWMWCMYMBN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39952002P | 2002-07-30 | 2002-07-30 | |
PCT/US2003/023430 WO2004010936A2 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006500335A JP2006500335A (ja) | 2006-01-05 |
JP4475406B2 true JP4475406B2 (ja) | 2010-06-09 |
Family
ID=31188592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004524883A Expired - Lifetime JP4475406B2 (ja) | 2002-07-30 | 2003-07-25 | 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 |
Country Status (8)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4475406B2 (ja) | 2002-07-30 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 |
US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
EP2287165A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
WO2005024057A1 (en) * | 2003-09-10 | 2005-03-17 | Galapagos Genomics N.V. | Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell |
GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
EP1780210A4 (en) * | 2004-08-11 | 2009-06-10 | Kyorin Seiyaku Kk | NEW CYCLIC AMINOBENOIC ACID DERIVATIVE |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
EP1862464A4 (en) * | 2005-03-23 | 2010-08-25 | Kyorin Seiyaku Kk | NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE |
EP2025674A1 (de) * | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JPWO2009087981A1 (ja) * | 2008-01-11 | 2011-05-26 | 株式会社Kri | 重合性化合物及びこの製造方法 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
WO2014123205A1 (ja) | 2013-02-06 | 2014-08-14 | 住友化学株式会社 | 縮合複素環化合物 |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
ES2929526T3 (es) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
CN108546245A (zh) * | 2018-05-22 | 2018-09-18 | 绍兴文理学院 | 一种抗增殖活性中间体ml-098的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4205080A (en) * | 1977-07-21 | 1980-05-27 | Shell Oil Company | 2,3-Dihydro benzofuran carboxamides |
US4213998A (en) * | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
US4213999A (en) * | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
DE3265715D1 (en) * | 1981-03-24 | 1985-10-03 | Fisons Plc | Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them |
JPS61158976A (ja) * | 1984-12-28 | 1986-07-18 | Shionogi & Co Ltd | ベンゾフランおよびベンゾチオフエン誘導体 |
FR2645537B1 (fr) * | 1989-04-05 | 1994-03-04 | Fabre Medicament Pierre | Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique |
US5273999A (en) * | 1991-09-10 | 1993-12-28 | Hoffmann-La Roche Inc. | Carboxylic acid leukotriene B4 antagonists |
US5352690A (en) * | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
JP3187611B2 (ja) * | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
US5516917A (en) * | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
WO2002060434A2 (en) * | 2000-10-31 | 2002-08-08 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
JP4475406B2 (ja) | 2002-07-30 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 |
-
2003
- 2003-07-25 JP JP2004524883A patent/JP4475406B2/ja not_active Expired - Lifetime
- 2003-07-25 US US10/522,259 patent/US7524882B2/en not_active Expired - Fee Related
- 2003-07-25 AT AT03771907T patent/ATE400564T1/de not_active IP Right Cessation
- 2003-07-25 CA CA002491733A patent/CA2491733A1/en not_active Abandoned
- 2003-07-25 AU AU2003256842A patent/AU2003256842B8/en not_active Ceased
- 2003-07-25 DE DE60322075T patent/DE60322075D1/de not_active Expired - Lifetime
- 2003-07-25 EP EP03771907A patent/EP1539136B1/en not_active Expired - Lifetime
- 2003-07-25 WO PCT/US2003/023430 patent/WO2004010936A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1539136A4 (en) | 2006-10-18 |
AU2003256842A1 (en) | 2004-02-16 |
JP2006500335A (ja) | 2006-01-05 |
EP1539136A2 (en) | 2005-06-15 |
AU2003256842B2 (en) | 2009-02-19 |
US20050228044A1 (en) | 2005-10-13 |
AU2003256842B8 (en) | 2009-06-18 |
WO2004010936A2 (en) | 2004-02-05 |
US7524882B2 (en) | 2009-04-28 |
CA2491733A1 (en) | 2004-02-05 |
DE60322075D1 (de) | 2008-08-21 |
WO2004010936A3 (en) | 2004-08-26 |
ATE400564T1 (de) | 2008-07-15 |
EP1539136B1 (en) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6645997B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
JP4505327B2 (ja) | 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 | |
US6713508B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
JP4475406B2 (ja) | 異常脂血症および他の脂質障害の治療用のPPARα選択的化合物 | |
RU2328483C2 (ru) | Индолы, обладающие противодиабетической активностью | |
JP2004513076A (ja) | 糖尿病治療で有用なn−置換インドール類 | |
AU2001292874A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
JP2004521124A (ja) | 糖尿病および脂質障害用の2−アリールオキシ−2−アリールアルカン酸類 | |
JP2003523336A (ja) | 糖尿病及び脂質障害のためのアリールオキシ酢酸 | |
AU2002248221A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
DE602005001265T2 (de) | Antidiabetische oxazolidindione und thiazolidindione | |
EP1796665B1 (en) | Compounds for the treatment of dyslipidemia and other lipid disorders | |
JP2008501027A (ja) | 抗糖尿病活性をもつベンゾ尿素 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100209 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100302 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 3 |